Paul A. Friedman's Insider Trades & SAST Disclosures
Paul A. Friedman's most recent trade in Madrigal Pharmaceuticals Inc was a trade of 1,105 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 25, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paul A. Friedman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 186,449 (1%) | 0% | 0 | Common Stock | |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 08 Apr 2024 | 26,270 | 212,005 (1%) | 0% | 9.5 | 248,252 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 26,270 | 206,256 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.86 per share. | 08 Apr 2024 | 5,663 | 201,171 (1%) | 0% | 244.9 | 1,386,646 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.96 per share. | 08 Apr 2024 | 5,028 | 194,065 (1%) | 0% | 247.0 | 1,241,710 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 248.59 per share. | 08 Apr 2024 | 4,866 | 185,735 (1%) | 0% | 248.6 | 1,209,642 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.12 per share. | 08 Apr 2024 | 3,730 | 206,834 (1%) | 0% | 244.1 | 910,566 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 247.76 per share. | 08 Apr 2024 | 3,464 | 190,601 (1%) | 0% | 247.8 | 858,241 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.71 per share. | 08 Apr 2024 | 2,078 | 199,093 (1%) | 0% | 245.7 | 510,591 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.95 per share. | 08 Apr 2024 | 1,441 | 210,564 (1%) | 0% | 243.0 | 350,094 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,613 | 213,348 (1%) | 0% | 9.5 | 260,943 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,613 | 232,526 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,407 | 278,849 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,407 | 213,142 (1%) | 0% | 9.4 | 258,996 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.34 per share. | 03 Apr 2024 | 18,806 | 187,556 (1%) | 0% | 245.3 | 4,613,823 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 18,710 | 260,139 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 18,710 | 204,445 (1%) | 0% | 9.5 | 176,810 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.20 per share. | 03 Apr 2024 | 9,264 | 195,373 (1%) | 0% | 243.2 | 2,253,016 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.42 per share. | 03 Apr 2024 | 6,679 | 204,637 (1%) | 0% | 242.4 | 1,619,098 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 241.07 per share. | 03 Apr 2024 | 6,273 | 198,172 (1%) | 0% | 241.1 | 1,512,222 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.25 per share. | 03 Apr 2024 | 5,299 | 192,873 (1%) | 0% | 242.2 | 1,283,679 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.35 per share. | 03 Apr 2024 | 5,228 | 186,179 (1%) | 0% | 245.3 | 1,282,669 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.58 per share. | 03 Apr 2024 | 4,301 | 206,362 (1%) | 0% | 244.6 | 1,051,959 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.22 per share. | 03 Apr 2024 | 3,966 | 191,407 (1%) | 0% | 244.2 | 968,588 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.14 per share. | 03 Apr 2024 | 2,549 | 188,230 (1%) | 0% | 245.1 | 624,857 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.64 per share. | 03 Apr 2024 | 2,294 | 210,663 (1%) | 0% | 243.6 | 558,921 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.31 per share. | 03 Apr 2024 | 1,821 | 185,735 (1%) | 0% | 246.3 | 448,530 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.13 per share. | 03 Apr 2024 | 1,558 | 186,672 (1%) | 0% | 246.1 | 383,471 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.00 per share. | 03 Apr 2024 | 1,467 | 191,406 (1%) | 0% | 243.0 | 356,482 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 240.10 per share. | 03 Apr 2024 | 1,420 | 211,928 (1%) | 0% | 240.1 | 340,939 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 247.14 per share. | 03 Apr 2024 | 737 | 185,935 (1%) | 0% | 247.1 | 182,141 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.31 per share. | 03 Apr 2024 | 627 | 190,779 (1%) | 0% | 244.3 | 153,185 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 241.15 per share. | 03 Apr 2024 | 612 | 211,316 (1%) | 0% | 241.1 | 147,582 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.92 per share. | 03 Apr 2024 | 444 | 185,735 (1%) | 0% | 245.9 | 109,189 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 248.42 per share. | 03 Apr 2024 | 200 | 185,735 (1%) | 0% | 248.4 | 49,685 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.00 per share. | 03 Apr 2024 | 185 | 212,957 (1%) | 0% | 242 | 44,770 | Common Stock |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 26,668 | 26,668 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Friedman A. Paul | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2023 | 2,254 | 20,001 (0%) | 0% | 243.9 | 549,796 | Common Stock |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 34,300 | 34,300 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 23,344 | 23,344 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Incyte Corp. | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 10,514 | 10,514 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 1,282 | 256,813 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges